The Alluminox™ platform combines drugs with localized light to selectively destroy cancer and immunosuppressive cells while sparing healthy tissue. Pre-clinical studies suggest it may also activate the immune system for lasting anti-tumor effects, positioning it as a potential precision, immune-activating surgical approach. Real-world data from Japan shows a manageable safety profile and strong efficacy, with an overall response rate over 68% and complete response rates exceeding 30% in head and neck cancer and 73% in nasopharyngeal cancer.
We at ABIES Capital are honored to participate in this year's most significant pharmaceutical licensing and signing dinner between Japan and Taiwan. Mickey Mikitani, CEO of Rakuten Medical, stated that this partnership expands RMI's impact in Asia through the Alluminox™ platform. The global RMI team continues to advance the scientific foundation and clinical application of their therapy. He expressed his enthusiasm for working with OEP and Cyntec to bring this treatment to patients in Taiwan, Malaysia, Singapore, and the Philippines.
【Rakuten Medical and Orient EuroPharma Sign Exclusive Licensing Agreement for Alluminox™ Platform-based Photoimmunotherapy in Taiwan, Malaysia, Singapore, and the Philippines】
